Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon has initiated construction of a new pharmaceutical development center at its existing manufacturing facility in Bourgoin-Jallieu, France. The new addition will enable the Bourgoin site to offer a full range of solid dose services as part of its Pharmaceutical Development Services (PDS) business.
Subscribe to our email newsletter
The company said that the facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes of up to 120kg. It will consist of a new pilot plant and equipment designed to contain high potency products.
Process trains will be scalable to commercial lines, offering clients the ability to produce phase 3 and commercial product in the same location.
Wes Wheeler, president and CEO of Patheon, said: “We currently provide our customers with solid dose Phase 3 and commercial supply from our facilities in North America. With this expansion we will offer the same services in Europe by the end of 2010. The investment reinforces our commitment to provide our customers with a full range of product development services – from pre-clinical through late phase stages, on to commercialisation.”